Clinical Trial

A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma

Name: A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma — clinical trial record (NCT07574528)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, multicenter phase II study evaluating sintilimab, pegaspargase, and selinexor followed by radiotherapy as first-line treatment for patients with newly diagnosed stage I/II extranodal natural killer/T-cell lymphoma (ENKTL).

Trial Details

NCT Number	NCT07574528
Lead Sponsor	Sun Yat-sen University
Conditions	NKTCL
Enrollment	47 participants
Start Date	2026-05-06
Primary Completion	2028-03-06 (estimated)
Study Completion	2031-05-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-08